期刊
CURRENT PHARMACEUTICAL DESIGN
卷 20, 期 41, 页码 6361-6374出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612820666140630101047
关键词
Alternative lengthening of telomeres; cancer; diagnosis; prognosis; telomerase; telomeres; therapy
资金
- Cancer Council New South Wales [PG11-08]
- National Health and Medical Research Council Australia [1034564, 1051897, 1051898, 1070881]
- Cancer Institute New South Wales
- Judith Hyam Memorial Trust Fund for Cancer Research
The presence of immortal cell populations with an up-regulated telomere maintenance mechanism (TMM) is an almost universal characteristic of cancers, whereas normal somatic cells are unable to prevent proliferation-associated telomere shortening and have a limited proliferative potential. TMMs and related aspects of telomere structure and function therefore appear to be ideal targets for the development of anticancer therapeutics. Such treatments would be targeted to a specific cancer-related molecular abnormality, and also be broad-spectrum in that they would be expected to be potentially applicable to most cancers. However, the telomere biology of normal and malignant human cells is a relatively young research field with large numbers of unanswered questions, so the optimal design of TMM-targeted therapeutic approaches remains unclear. This review outlines the opportunities and challenges presented by telomeres and TMMs for clinical management of cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据